Irritable Bowel Syndrome, Pain-Predominant (Investigational Adjunct)
Investigational adjunct for pain-predominant IBS refractory to dietary and pharmacologic therapy; low-FODMAP diet, antispasmodics, low-dose tricyclic antidepressants, and cognitive behavioral therapy or gut-directed hypnotherapy remain evidence-based.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for irritable bowel syndrome, pain-predominant. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
- What evidence exists?
- Tier C (investigational). No clinical study of leech therapy for IBS was identified in PubMed or Europe PMC. Evidence-based first-line management is dietary intervention (a limited low-FODMAP trial is recommended in the 2021 ACG guideline (conditional recommendation, very low-quality evidence)), antispasmodics (hyoscyamine, peppermint oil), tricyclic antidepressants or SNRIs for pain, soluble fiber for constipation-predominant subtypes, eluxadoline or rifaximin for diarrhea-predominant or mixed subtypes, gut-directed hypnotherapy, and cognitive behavioral therapy.
- Main risks
- Bleeding from each bite site for 6 to 10 hours after the leech detaches
- Iron-deficiency anemia from cumulative blood loss across multiple sessions
- Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
- Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
- Small Y-shaped bite marks or skin colour changes at the bite sites, which usually fade over weeks to months
- Local pain, bruising, swelling, or itching for 1 to 3 days after each session
- Bowel symptom flare around session days from stress and dietary disruption
- Distraction from evidence-based dietary and pharmacologic interventions
- Who should not consider this
- Patients with alarm features (rectal bleeding, weight loss, anemia, age over 50 without prior workup) — need GI workup first
- Patients who have not tried low-FODMAP diet, antispasmodics, or appropriate medications
- Patients with possible inflammatory bowel disease or celiac disease that has not been ruled out
- Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran or heparin (daily aspirin alone is not a contraindication: tell your doctor, who starts with fewer leeches)
- People with hemophilia or any other inherited bleeding disorder
- Patients with anemia
- People with an active infection at the planned application site
- What to ask your clinician
- Have I had appropriate IBS workup excluding IBD, celiac, and other mimics?
- Have I tried low-FODMAP diet under a dietitian's guidance?
- Have I tried antispasmodics, peppermint oil, or a tricyclic antidepressant?
- Have CBT or gut-directed hypnotherapy been considered?
- What is the published evidence base for leeches in IBS?
- How will success be measured?
- When to seek urgent care
- Bleeding from a bite site that soaks through more than one dressing per hour
- Bleeding that continues more than 24 hours after the leech detached
- Spreading redness, warmth, swelling, pus, or red streaks around any bite site
- Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
- Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
- Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
- Rectal bleeding, black or tarry stools, unintentional weight loss
- Nighttime diarrhea waking from sleep
- Severe abdominal pain not typical of IBS pattern
What this does NOT mean
- It does not mean leech therapy is FDA-cleared for IBS — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
- It does not replace low-FODMAP diet, antispasmodics, or psychological therapies.
- It does not change the gut-brain axis dysregulation underlying IBS.
- It does not exclude or treat IBD, celiac, or other mimics.
- No clinical study of leech therapy in IBS was identified, so its effect is unknown.
Safety cross-references
Clinical Profile
- Category
- Gastrointestinal
- ICD-10
- K58.0, K58.1, K58.2, K58.8, K58.9
- Safety tier
- Medium
Evidence Summary
Irritable bowel syndrome (Rome IV) is recurrent abdominal pain associated with defecation or change in bowel habits, in the absence of structural disease. Pain-predominant phenotypes overlap with IBS-D, IBS-C, and IBS-M. Evidence-based management is dietary trial (low-FODMAP, with structured reintroduction), antispasmodics (hyoscine, peppermint oil), low-dose tricyclic antidepressants for pain, SSRIs for IBS-C with mood comorbidity, and gut-directed hypnotherapy or cognitive behavioral therapy with substantial RCT support. Linaclotide, plecanatide, and lubiprostone for IBS-C; eluxadoline, rifaximin, and alosetron for IBS-D. No clinical study or case report of leech therapy for irritable bowel syndrome was identified in PubMed, Europe PMC, Crossref, ClinicalTrials.gov or Russian- and German-language web searches (searched October 2026), and the 2004 Baskova and Isakhanyan monograph reports none; a popular Russian leech-therapy guide lists irritable bowel among its indications without presenting any data.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)
Contraindications
- Hemophilia or another bleeding disorder
- Taking anticoagulants (blood thinners such as warfarin or heparin)
- Anemia or suppressed blood formation
- Low blood pressure, shock, collapse or fainting
- Severe wasting (cachexia)
- Intolerance of leeches or a history of severe allergic reactions
- Pregnancy
- Stomach or duodenal ulcer, erosive gastritis
- Acute infectious disease or high fever
- Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
- Drinking alcohol at the time of treatment
- No consent from the patient
- Alarm features (weight loss, GI bleeding, anemia, family history of GI cancer) — workup first
- Inflammatory bowel disease
- Active gastroenteritis or post-infectious IBS within 8 weeks
- Stoma, ventral hernia, or abdominal wall pathology at placement site
- Pregnancy or lactation
Related Conditions
Chronic Pancreatitis (Investigational Pain Adjunct)
Highly investigational adjunct for chronic pancreatitis pain refractory to conventional therapy; no clinical study identified; pancreatic enzyme replacement and pain medicine remain primary.
Functional Dyspepsia (Investigational Adjunct)
Investigational adjunct for functional dyspepsia (Rome IV criteria); H. pylori eradication when positive, proton pump inhibitors, prokinetics, and tricyclic antidepressants remain evidence-based.
Ulcerative Proctitis (Investigational Adjunct)
Highly investigational adjunct for distal ulcerative proctitis; no clinical study found; topical 5-ASA and corticosteroids remain primary.
Hemorrhoids (Grade II-III, Symptomatic)
Investigational use for symptomatic relief of grade II-III internal/external hemorrhoidal disease; does not address anatomic prolapse.